Metastatic Breast Cancer: Advances in Treatment and Management

Target Audience
This activity was developed for oncology nurses and pharmacists who wish to enhance their competence concerning the treatment of patients with metastatic breast cancer.

Educational Objectives
At the completion of this educational activity, participants should be able to:

• Discuss the impact of metastatic breast cancer and key parameters for disease stratification
• Describe the role of prognostic/genetic markers and tumor histology in classifying breast cancer subtypes and predicting treatment response
• Review advances in the treatment of metastatic breast cancer, including the role of endocrine therapy, chemotherapy, targeted therapy, and bisphosphonates, with emphasis on targeted therapies
• Examine effective patient-tailored treatment approaches, based on recent data and clinical practice guidelines

Instructions for Credit
There is no fee for this activity. To receive credit, participants must read this CE activity in its entirety and complete the posttest and evaluation. The posttest and evaluation can be completed online at www.mlicme.org/p10078.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70%or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.

For questions regarding the accreditation of this activity, please contact MedicalLearning Institute at (609) 333-1693 or cgusack@mlicme.org.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.

Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.5 contact hours (0.15 CEUs) of continuing education credit. The universal programnumber for this activity is 0468-9999-11-001-H01-P.

Disclosures
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer( s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months.

Peer reviewers—Jayshree Shah, RN, APN-C,MSN, BSN, BS, is on the speakers’ bureau for Bristol-Myers Squibb, Celgene,Merck, and Novartis, and is on the advisory board for Bristol-Myers Squibb and Novartis. Nancy Nesser, JD, PharmD, has nothing to disclose.

Faculty Disclosures
Joanna Schwartz, PharmD, BCOP, has nothing to disclose.

Georgia Litsas, MSN, ANP-BC, AOCNP, is on the speakers’ bureau for Genentech, Novartis, and Pfizer.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Trade names used in this supplement are for the learner’s reference only.No promotion of or bias toward any product should be inferred.

Estimated time to complete this activity: 1 hour